Cargando…
Evidence for an Additive Neurorestorative Effect of Simultaneously Administered CDNF and GDNF in Hemiparkinsonian Rats: Implications for Different Mechanism of Action
Parkinson’s disease (PD) is a neurodegenerative disorder associated with a progressive loss of dopaminergic (DAergic) neurons of the substantia nigra (SN) and the accumulation of intracellular inclusions containing α-synuclein. Current therapies do not stop the progression of the disease, and the ef...
Autores principales: | Voutilainen, Merja H., De Lorenzo, Francesca, Stepanova, Polina, Bäck, Susanne, Yu, Li-Ying, Lindholm, Päivi, Pörsti, Eeva, Saarma, Mart, Männistö, Pekka T., Tuominen, Raimo K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346176/ https://www.ncbi.nlm.nih.gov/pubmed/28303260 http://dx.doi.org/10.1523/ENEURO.0117-16.2017 |
Ejemplares similares
-
Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease
por: Bäck, Susanne, et al.
Publicado: (2013) -
Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease
por: Garea-Rodríguez, Enrique, et al.
Publicado: (2016) -
CDNF and MANF regulate ER stress in a tissue-specific manner
por: Pakarinen, Emmi, et al.
Publicado: (2022) -
GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020) -
Neuroprotective Potential of a Small Molecule RET Agonist in Cultured Dopamine Neurons and Hemiparkinsonian Rats
por: Renko, Juho-Matti, et al.
Publicado: (2021)